Drug intelligence / Profile preview

napabucasin + gemcitabine + nab-paclitaxel

Development stage: Unknown
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Oral (napabucasin), Intravenous (gemcitabine, Nab-paclitaxel)

Overview

**Napabucasin + gemcitabine + nab-paclitaxel** is a combination chemotherapy regimen investigated for the first-line treatment of metastatic pancreatic adenocarcinoma. **Napabucasin** is an investigational oral small molecule drug that acts as a reactive oxygen species (ROS) generator and is bioactivated by NAD(P)H:quinone oxidoreductase 1 (NQO1), targeting cancer stem cell pathways and inhibiting multiple oncogenic signaling pathways, including signal transducer and activator of transcription 3 (STAT3)[1][3]. **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis, causing cytotoxicity in rapidly dividing cells[3][4][8]. **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor disrupting cell division, designed to improve delivery and reduce solvent-related toxicity[4][8]. The regimen was studied in phase 3 trials (CanStem111P) but did not show improved survival compared to gemcitabine plus nab-paclitaxel alone[1][3].

Brand names: Abraxane (nab-paclitaxel)Gemzar (gemcitabine)
Other names: napabucasin + gemcitabine + nab-paclitaxel

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)DNA polymerase familyNQO1

Beyond the preview

Go deeper on napabucasin + gemcitabine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on napabucasin + gemcitabine + nab-paclitaxel.

Explore the full profile